| Dr Tu V Nguyen, MD | |
|
9920 Talbert Ave, Fountain Valley, CA 92708-5153 | |
| (714) 378-7000 | |
| (714) 647-1245 |
| Full Name | Dr Tu V Nguyen |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 27 Years |
| Location | 9920 Talbert Ave, Fountain Valley, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114931961 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 240385 (New York) | Secondary |
| 207L00000X | Anesthesiology | A105350 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Hospital | Bangor, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Joseph Hospital | 6406766336 | 155 |
News Archive
A computer algorithm did a better job than doctors at documenting "red flag" symptoms among patients with gastrointestinal disorders, a Cedars-Sinai study has found, underscoring the potential of the technology to improve patient care.
Patients with unexplained low blood counts and abnormally mutated cells who do not fit the diagnostic criteria for recognized blood cancers should be described as having clonal cytopenias of undetermined significance (CCUS), suggest University of California, San Diego School of Medicine researchers in a recent paper published in the journal Blood.
Investigators at Burnham Institute for Medical Research (Burnham) and colleagues have identified a novel mouse gene (Rps23r1) that reduces the accumulation of two toxic proteins that are major players in Alzheimer's disease: amyloid beta and tau. The amyloid and tau lowering functions of this gene were demonstrated in both human and mouse cells.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid" technology.
Emdeon Inc., one of the largest health information networks in the nation focusing on clinical exchange and a leading provider of healthcare revenue and payment cycle management solutions, today announced the selection of IBM as its technology provider for patient-centric clinical information exchange.
› Verified 7 days ago
| Entity Name | St Joseph Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154321545 PECOS PAC ID: 6406766336 Enrollment ID: O20040604000895 |
News Archive
A computer algorithm did a better job than doctors at documenting "red flag" symptoms among patients with gastrointestinal disorders, a Cedars-Sinai study has found, underscoring the potential of the technology to improve patient care.
Patients with unexplained low blood counts and abnormally mutated cells who do not fit the diagnostic criteria for recognized blood cancers should be described as having clonal cytopenias of undetermined significance (CCUS), suggest University of California, San Diego School of Medicine researchers in a recent paper published in the journal Blood.
Investigators at Burnham Institute for Medical Research (Burnham) and colleagues have identified a novel mouse gene (Rps23r1) that reduces the accumulation of two toxic proteins that are major players in Alzheimer's disease: amyloid beta and tau. The amyloid and tau lowering functions of this gene were demonstrated in both human and mouse cells.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid" technology.
Emdeon Inc., one of the largest health information networks in the nation focusing on clinical exchange and a leading provider of healthcare revenue and payment cycle management solutions, today announced the selection of IBM as its technology provider for patient-centric clinical information exchange.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tu V Nguyen, MD 210 N Tustin Ave, Santa Ana, CA 92705-3807 Ph: (714) 347-1000 | Dr Tu V Nguyen, MD 9920 Talbert Ave, Fountain Valley, CA 92708-5153 Ph: (714) 378-7000 |
News Archive
A computer algorithm did a better job than doctors at documenting "red flag" symptoms among patients with gastrointestinal disorders, a Cedars-Sinai study has found, underscoring the potential of the technology to improve patient care.
Patients with unexplained low blood counts and abnormally mutated cells who do not fit the diagnostic criteria for recognized blood cancers should be described as having clonal cytopenias of undetermined significance (CCUS), suggest University of California, San Diego School of Medicine researchers in a recent paper published in the journal Blood.
Investigators at Burnham Institute for Medical Research (Burnham) and colleagues have identified a novel mouse gene (Rps23r1) that reduces the accumulation of two toxic proteins that are major players in Alzheimer's disease: amyloid beta and tau. The amyloid and tau lowering functions of this gene were demonstrated in both human and mouse cells.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid" technology.
Emdeon Inc., one of the largest health information networks in the nation focusing on clinical exchange and a leading provider of healthcare revenue and payment cycle management solutions, today announced the selection of IBM as its technology provider for patient-centric clinical information exchange.
› Verified 7 days ago
Dr. Sandra W Kluwe, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 17100 Euclid St, Fountain Valley, CA 92708 Phone: 714-979-1211 | |
Elsa A. Tekle, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 17100 Euclid St, Fountain Valley, CA 92708 Phone: 714-949-1211 | |
Dr. Michael Henry Wong, D.O. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 10900 Warner Ave, Suite #101 A, Fountain Valley, CA 92708 Phone: 714-698-1270 Fax: 714-962-7261 | |
Michael Audon, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 10900 Warner Ave, Suite 101a, Fountain Valley, CA 92708 Phone: 714-285-2385 Fax: 818-831-1808 | |
Dr. Bharat V Merai, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 17100 Euclid St, Fountain Valley, CA 92708 Phone: 714-979-1211 | |
Alan Ho, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 18035 Brookhurst St, # 1200, Fountain Valley, CA 92708 Phone: 714-963-7240 |